MG Card for ABO/RhD+Reverse Grouping

Changchun Bioxun Biotech Co., Ltd.

Changchun, China

Bioxun is a hi-tech in-vitro diagnostic reagents producing enterprise established in July 2001. She independently developed microcolumn gel immunoassay (MGIA) technology which has replaced the traditional test tubes method of blood group testing, antibody screening, and cross matching. This technology has also made the anti-human globulin test (Coombs test) becomes a routine clinical test, and has solved the problems of detecting mixed blood sample and other issues. Bion has taken the Chinese MGIA detection technology to an advanced international level. Bioxun is committed to the development of new advanced cost effective products. Bioxun pioneered the development of micro-column gel platelet antibody detection technology that has the same advantages as the micro-column gel red blood cell antibody detection technology. This micro-column gel platelet antibody detection technology is simple to use, requires less time, ensuring safe, convenient and effective clinical blood transfusion. In 2014, Bioxun established a global strategic partnership with Hamilton Bonaduz AG, a Swiss manufacturer of automated inspection equipment. Bioxun and Hamilton jointly developed a micro-column gel detection card automatic blood type analyzer to meet customer needs. We have a strong technical work force equipped with state of the art automatic production lines, dedicated to provide quality and efficient products for our customers. At the same time, we also provide timely and thoughtful after-sales service and technical support. As a leader in China with many national and international competitors, Bioxun Company is striving to build a global brand.